Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier
function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar …

We would like to thank the interest of Kow et al. in our study. In the letter, they expressed
their skepticism that therapeutic dose anticoagulation therapy can reduce mortality in …

Introduction: As the coronavirus disease (COVID-19) spreads worldwide, awaiting the
development of a vaccine, researchers are looking among the arsenal of available drugs, for …

Background The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive
increase in the number of intensive care unit (ICU) admissions with acute respiratory …

COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide.
The high reported morbidity has been related to hypoxia and inflammation leading to …

The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is
still raging. However, the pathophysiology of acute and post-acute manifestations of COVID …

Background Imatinib reduced 90-day mortality in hospitalised coronavirus disease 2019
(COVID-19) patients in a recent clinical trial, but the biological effects that cause improved …

The involvement of the vascular endothelium in the complications of coronavirus disease
2019 is now recognized. Chief among these are pulmonary endotheliitis, cytokine storm …

Since the beginning of the COVID-19 pandemic, there has been an urgent need to find
effective treatment. It is widely known that virus attacks and damages mostly the lungs, but …

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generated a
worldwide emergency, until the declaration of the pandemic in March 2020. SARS-CoV-2 …